Evidence map›Paper›PMID 32544571›Full record

ReviewMolecular metabolism2020

Roles of bone-derived hormones in type 2 diabetes and cardiovascular pathophysiology.

Xuzhu Lin, Danise-Ann Onda, Chieh-Hsin Yang, Joshua R Lewis, Itamar Levinger, Kim Loh

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Molecular metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
3.0field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 36 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Sclerostin: From Molecule to Clinical Biomarker.International journal of molecular sciences · 2022
    Review
  16. Observational
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Xuzhu LinSt. Vincent's Institute of Medical Research, Fitzroy, VIC, Australia. Electronic address: slin@svi.edu.au.
Danise-Ann OndaSt. Vincent's Institute of Medical Research, Fitzroy, VIC, Australia.
Chieh-Hsin YangSt. Vincent's Institute of Medical Research, Fitzroy, VIC, Australia.
Joshua R LewisSchool of Medical and Health Sciences, Edith Cowan University, Perth, Australia; Medical School, University of Western Australia, Perth, Australia.
Itamar LevingerInstitute for Health and Sport (IHES), Victoria University, Footscray, VIC, Australia; Australian Institute for Musculoskeletal Science (AIMSS), University of Melbourne and Western Health, St Albans, VIC, Australia.
Kim LohSt. Vincent's Institute of Medical Research, Fitzroy, VIC, Australia; Department of Medicine, University of Melbourne, Parkville, VIC, Australia. Electronic address: kloh@svi.edu.au.
St Vincents Institute of Medical Research · AUEdith Cowan University · AUWestern Health · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundEmerging evidence demonstrates that bone is an endocrine organ capable of influencing multiple physiological and pathological processes through the secretion of hormones. Recent research suggests complex crosstalk between the bone and other metabolic and cardiovascular tissues. It was uncovered that three of these bone-derived hormones-osteocalcin, lipocalin 2, and sclerostin-are involved in the endocrine regulations of cardiometabolic health and play vital roles in the pathophysiological process of developing cardiometabolic syndromes such as type 2 diabetes and cardiovascular disease. Chronic low-grade inflammation is one of the hallmarks of cardiometabolic diseases and a major contributor to disease progression. Novel evidence also implicates important roles of bone-derived hormones in the regulation of chronic inflammation. SCOPE OF REVIEW: In this review, we provide a detailed overview of the physiological and pathological roles of osteocalcin, lipocalin 2, and sclerostin in cardiometabolic health regulation and disease development, with a focus on the modulation of chronic inflammation. MAJOR

conclusionsEvidence supports that osteocalcin has a protective role in cardiometabolic health, and an increase of lipocalin 2 contributes to the development of cardiometabolic diseases partly via pro-inflammatory effects. The roles of sclerostin appear to be complicated: It exerts pro-adiposity and pro-insulin resistance effects in type 2 diabetes and has an anti-calcification effect during cardiovascular disease. A better understanding of the actions of these bone-derived hormones in the pathophysiology of cardiometabolic diseases will provide crucial insights to help further research develop new therapeutic strategies to treat these diseases.

Indexed as

Adaptor Proteins, Signal TransducingBone and BonesCardiovascular DiseasesDiabetes Mellitus, Type 2HormonesHumansInflammationInsulin ResistanceLipocalin-2ObesityOsteocalcinAdaptor Proteins, Signal TransducingHormonesLipocalin-2OsteocalcinSOST protein, humanBone-derived hormonesCardiometabolic healthCardiovascular diseaseChronic inflammationLipocalin 2OsteocalcinSclerostinType 2 diabetes

Identifiers

PMID32544571
PMCPMC7348059
OpenAlexW3035413399

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.